 BEDFORD, Mass.--BUSINESS WIRE--Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, announced today the upcoming presentation of new preclinical data on STK-002 at The Association for Research in Vision and Ophthalmology ARVO 2022 Annual Meeting being held May 1-4, 2022 in Denver, Colorado. STK-002 is a proprietary antisense oligonucleotide ASO in precli 